Abstract:As one of the most common breast cancer subtypes, luminal A breast cancer is sensitive to endocrine-based therapy and insensitive to chemotherapy. Patients with luminal A subtype of breast cancer have a relatively good prognosis compared with that of patients with other subtypes of breast cancer. However, with the increased incidence in endocrine resistance and severe side effects, simple endocrine therapy has become unsuitable for the treatment of luminal A breast cancer. Therefore, identifying novel therapeutic targets for luminal A breast cancer may accelerate the development of an effective therapeutic strategy. The bioinformatical analysis of the current study, which included KEGG and GO analyses of the GSE20437 dataset containing 24 healthy and 18 breast cancer tissue samples, identified key target genes associated with breast cancer. Moreover, survival analysis results revealed that a low expression of BTG2 was significantly associated with the low survival rate of patients with breast cancer, indicated that B-cell translocation gene 2 (BTG2) may be a potential target in breast cancer. However, BTG2 may be cancer type-dependent, as overexpression of BTG2 has been demonstrated to suppress the proliferation of pancreatic and lung cancer cells, but promote the proliferation of bladder cancer cells. Since the association between BTG2 and luminal A-subtype breast cancer remains unclear, it is important to understand the biological function of BTG2 in luminal A breast cancer. Based on the expression levels of estrogen receptor, progesterone receptor and human epidermal growth factor receptor, MCF-7 cells were selected in the present study as a luminal A breast cancer cell type. MTT, Transwell invasion and wound healing assays revealed that overexpression of BTG2 suppressed the levels of MCF-7 cell proliferation, migration and invasion. In addition, the downregulation of BTG2 at the mRNA and protein level was also confirmed in luminal A breast tumor tissue, which was consistent with the results in vitro. These results indicated that BTG2 may act as an effective target for the treatment of luminal A breast cancer.

BTG/TOB Antiproliferative Protein Family and Tumors

Molecular cloning and characterization of a novel human BTB domain-containing gene, , which is down-regulated in glioma

Comprehensive Pancancer Analysis of TUBB6 as a Marker for Prognosis and Immunotherapy Response

Expression and Prognosis Analyses of the Tob/BTG Antiproliferative (APRO) Protein Family in Human Cancers

BTG2 overexpression increases the radiosensitivity of breast cancer cells in vitro and in vivo.

Enhanced radiosensitivity of NSCLC cells by transducer of erbB2.1 (TOB1) through modulation of the MAPK/ERK pathway.

The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis

Suppression of Human Lung Cancer Cell Proliferation and Metastasis in Vitro by the Transducer of ErbB-2.1 (TOB1)

Btg1 Expression Correlates With The Pathogenesis And Progression Of Ovarian Carcinomas

Transcriptomic Analyses Reveal B-Cell Translocation Gene 2 as a Potential Therapeutic Target in Ovarian Cancer

A pan-cancer analysis of anti-proliferative protein family genes for therapeutic targets in cancer

BTG2 As a Tumor Target for the Treatment of Luminal A Breast Cancer

B‑cell translocation 1 gene inhibits cellular metastasis‑associated behavior in breast cancer.

Cloning of the mouse BTG3 gene and definition of a new gene family (the BTG family) involved in the negative control of the cell cycle

Research Progress of BTG2 As a Tumor Prognostic Factor

Tob1 Suppresses Invasive Phenotype of Human Breast Cancer

Expression of B-cell Translocation Gene 2 is Associated with Favorable Prognosis in Hepatocellular Carcinoma Patients and Sensitizes Irradiation-Induced Hepatocellular Carcinoma Cell Apoptosis in Vitro and in Nude Mice.

Btg1 Inhibits Breast Cancer Cell Growth Through Induction Of Cell Cycle Arrest And Apoptosis

Clinicopathological significance of cytoplasmic transducer of ErbB2. 1 expression in gastric cancer.

The Role of the TOB1 Gene in Growth Suppression of Hepatocellular Carcinoma.

BTG2 Inhibits the Proliferation and Metastasis of Osteosarcoma Cells by Suppressing the PI3K/AKT Pathway.